Vir Biotechnology, Inc. (VIR) Balance Sheet

The steady decline in total assets from $1.8B to $1.2B over the same period reflects ongoing cash consumption for R&D, with no offsetting revenue growth. This trajectory suggests the company is in a sustained investment phase, and investors should monitor whether upcoming clinical milestones can reverse the equity drawdown.

The temporary debt increase appears to have been a strategic move to bolster liquidity ahead of a milestone payment, given the subsequent reduction. With D/E now at 0.09, leverage remains conservative, but the volatility suggests Vir may use debt opportunistically to bridge funding gaps, which warrants monitoring for refinancing risk.

The shrinking PPE base suggests Vir is outsourcing manufacturing and focusing on R&D, consistent with a clinical-stage biotech. The stable goodwill implies acquisitions have not led to write-downs, but investors should watch for any future impairments if pipeline assets underperform.

The equity base is being eroded by ongoing R&D spending, with no dividends or buybacks to support shareholder returns. This suggests the company is prioritizing pipeline development over capital preservation, and the equity quality is dependent on future clinical success to justify the accumulated losses.

Despite the equity decline, Vir's liquidity position is strong, with cash and current assets far exceeding current liabilities. The current ratio above 6 indicates the company can fund operations for several quarters without additional financing, though the burn rate of over $100M per quarter suggests a runway of roughly two years at current cash levels.